Exact Mass: 363.0469978
Exact Mass Matches: 363.0469978
Found 152 metabolites which its exact mass value is equals to given mass value 363.0469978,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Flufenacet
C14H13F4N3O2S (363.06645660000004)
CONFIDENCE standard compound; INTERNAL_ID 255; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9423; ORIGINAL_PRECURSOR_SCAN_NO 9420 CONFIDENCE standard compound; INTERNAL_ID 255; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9408; ORIGINAL_PRECURSOR_SCAN_NO 9406 CONFIDENCE standard compound; INTERNAL_ID 255; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9375; ORIGINAL_PRECURSOR_SCAN_NO 9373 CONFIDENCE standard compound; INTERNAL_ID 255; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9386; ORIGINAL_PRECURSOR_SCAN_NO 9384 CONFIDENCE standard compound; INTERNAL_ID 255; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9401; ORIGINAL_PRECURSOR_SCAN_NO 9399 CONFIDENCE standard compound; INTERNAL_ID 255; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9344; ORIGINAL_PRECURSOR_SCAN_NO 9342 CONFIDENCE standard compound; INTERNAL_ID 8396 CONFIDENCE standard compound; INTERNAL_ID 3800
Cefadroxil
C16H17N3O5S (363.08888720000004)
Cefadroxil is only found in individuals that have used or taken this drug. It is a long-acting, broad-spectrum, water-soluble, cephalexin derivative.Like all beta-lactam antibiotics, cefadroxil binds to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, causing the inhibition of the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that cefadroxil interferes with an autolysin inhibitor. J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01D - Other beta-lactam antibacterials > J01DB - First-generation cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D002511 - Cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic CONFIDENCE standard compound; EAWAG_UCHEM_ID 3662
Guanosine monophosphate
C10H14N5O8P (363.05799740000003)
Guanosine monophosphate (GMP), also known as 5′-guanidylic acid or guanylic acid (conjugate base guanylate), is a nucleotide that is used as a monomer in RNA. It is an ester of phosphoric acid with the nucleoside guanosine. GMP consists of the phosphate group, the pentose sugar ribose, and the nucleobase guanine; hence it is a ribonucleoside monophosphate. Guanosine monophosphate is commercially produced by microbial fermentation. Guanosine monophosphate, also known as guanylic acid or 5-GMP, belongs to the class of organic compounds known as purine ribonucleoside monophosphates. These are nucleotides consisting of a purine base linked to a ribose to which one monophosphate group is attached. A guanine nucleotide containing one phosphate group esterified to the sugar moiety and found widely in nature. Guanosine monophosphate exists in all living species, ranging from bacteria to humans. Within humans, guanosine monophosphate participates in a number of enzymatic reactions. In particular, guanosine triphosphate and guanosine monophosphate can be biosynthesized from diguanosine tetraphosphate through its interaction with the enzyme bis(5-nucleosyl)-tetraphosphatase [asymmetrical]. In addition, guanosine monophosphate can be biosynthesized from guanosine diphosphate; which is mediated by the enzyme ectonucleoside triphosphate diphosphohydrolase 5. In humans, guanosine monophosphate is involved in the metabolic disorder called the lesch-nyhan syndrome (lns) pathway. Outside of the human body, guanosine monophosphate has been detected, but not quantified in several different foods, such as common cabbages, tea, winter squash, spearmints, and sugar apples. Guanosine-5-monophosphate, also known as 5-gmp or guanylic acid, is a member of the class of compounds known as purine ribonucleoside monophosphates. Purine ribonucleoside monophosphates are nucleotides consisting of a purine base linked to a ribose to which one monophosphate group is attached. Guanosine-5-monophosphate is slightly soluble (in water) and a moderately acidic compound (based on its pKa). Guanosine-5-monophosphate can be found in a number of food items such as mustard spinach, swiss chard, watercress, and colorado pinyon, which makes guanosine-5-monophosphate a potential biomarker for the consumption of these food products. Guanosine-5-monophosphate can be found primarily in blood and saliva, as well as throughout most human tissues. Guanosine-5-monophosphate exists in all living species, ranging from bacteria to humans. In humans, guanosine-5-monophosphate is involved in several metabolic pathways, some of which include clarithromycin action pathway, erythromycin action pathway, minocycline action pathway, and tetracycline action pathway. Guanosine-5-monophosphate is also involved in several metabolic disorders, some of which include gout or kelley-seegmiller syndrome, xanthine dehydrogenase deficiency (xanthinuria), aICA-Ribosiduria, and molybdenum cofactor deficiency. Guanosine monophosphate is known as E number reference E626.[7] In the form of its salts, such as disodium guanylate (E627), dipotassium guanylate (E628) and calcium guanylate (E629), are food additives used as flavor enhancers to provide the umami taste.[7] It is often used in synergy with disodium inosinate; the combination is known as disodium 5′-ribonucleotides. Disodium guanylate is often found in instant noodles, potato chips and snacks, savoury rice, tinned vegetables, cured meats, and packet soup. As it is a fairly expensive additive, it is usually not used independently of glutamic acid or monosodium glutamate (MSG), which also contribute umami. If inosinate and guanylate salts are present in a list of ingredients but MSG does not appear to be, the glutamic acid is likely provided as part of another ingredient, such as a processed soy protein complex (hydrolyzed soy protein), autolyzed yeast, or soy sauce. 5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway. 5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway.
Guanosine 3'-monophosphate
C10H14N5O8P (363.05799740000003)
Guanosine 3-monophosphate, also known as 3-GMP or 3-guanylic acid, belongs to the class of organic compounds known as purine nucleosides. Purine nucleosides are compounds comprising a purine base attached to a ribosyl or deoxyribosyl moiety. Guanosine 3-monophosphate has been identified in the human placenta (PMID: 32033212).
Cyclic pyranopterin monophosphate
C10H14N5O8P (363.05799740000003)
Cyclic pyranopterin monophosphate, also known as cpmp or precursor z, hydrated, belongs to pyranopterins and derivatives class of compounds. Those are pterin derivatives in which a pyran ring is fused either to the pyrimidine ring or the pyrazine ring of the pterin moiety. Cyclic pyranopterin monophosphate is slightly soluble (in water) and an extremely strong acidic compound (based on its pKa). Cyclic pyranopterin monophosphate can be found in a number of food items such as european cranberry, vaccinium (blueberry, cranberry, huckleberry), peanut, and dill, which makes cyclic pyranopterin monophosphate a potential biomarker for the consumption of these food products. Cyclic pyranopterin monophosphate exists in all living organisms, ranging from bacteria to humans. Cyclic pyranopterin monophosphate (cPMP) is an experimental treatment for molybdenum cofactor deficiency type A, which was developed by José Santamaría-Araujo and Guenter Schwarz at the German universities TU Braunschweig and the University of Cologne . A - Alimentary tract and metabolism > A16 - Other alimentary tract and metabolism products > A16A - Other alimentary tract and metabolism products > A16AX - Various alimentary tract and metabolism products Cyclic pyranopterin monophosphate is part of the Cofactor biosynthesis, Folate biosynthesis, and Sulfur relay system pathways. It is a substrate for: Molybdopterin synthase catalytic subunit. C78272 - Agent Affecting Nervous System
Benzoximate
C18H18ClNO5 (363.08734480000004)
D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents > D007096 - Imidoesters
8-Oxo-dGMP
C10H14N5O8P (363.05799740000003)
8-Oxo-dGMP is a metabolite of 8-oxo-dGTP. 8-Oxo-7,8-dihydro-2-deoxyguanosine 5-triphosphate (8-oxo-dGTP) is a potent mutagenic substrate for DNA synthesis. 8-Oxo-dGTP is rapidly degraded to 8-oxo-dGMP by cellular 8-oxo-dGTPase activity. 8-Oxo-dGMP is further degraded to 8-oxo-deoxyguanosine by a nucleotidase. 8-Oxo-dGMP is the most preferred substrate of this nucleotidase enzyme (PMID: 7819228). The human MutT homologue (hMTH1), an 8-oxo-dGTPase, prevents misincorporation of 8-oxo-dGTP into DNA by hydrolyzing it to 8-oxo-dGMP. hMTH1 mRNA is overexpressed in human renal cell carcinomas and breast tumors. Likewise, elevated levels of hMTH1 protein have also been detected in brain tumors. (PMID: 12757855) [HMDB] 8-Oxo-dGMP is a metabolite of 8-oxo-dGTP. 8-Oxo-7,8-dihydro-2-deoxyguanosine 5-triphosphate (8-oxo-dGTP) is a potent mutagenic substrate for DNA synthesis. 8-Oxo-dGTP is rapidly degraded to 8-oxo-dGMP by cellular 8-oxo-dGTPase activity. 8-Oxo-dGMP is further degraded to 8-oxo-deoxyguanosine by a nucleotidase. 8-Oxo-dGMP is the most preferred substrate of this nucleotidase enzyme (PMID: 7819228). The human MutT homologue (hMTH1), an 8-oxo-dGTPase, prevents misincorporation of 8-oxo-dGTP into DNA by hydrolyzing it to 8-oxo-dGMP. hMTH1 mRNA is overexpressed in human renal cell carcinomas and breast tumors. Likewise, elevated levels of hMTH1 protein have also been detected in brain tumors. (PMID: 12757855).
Bismuth subsalicylate
D000893 - Anti-Inflammatory Agents > D000894 - Anti-Inflammatory Agents, Non-Steroidal > D012459 - Salicylates C26170 - Protective Agent > C2459 - Chemoprotective Agent > C2080 - Cytoprotective Agent C78276 - Agent Affecting Digestive System or Metabolism > C266 - Antidiarrheal Agent D005765 - Gastrointestinal Agents > D000930 - Antidiarrheals
Guanosine 2'-monophosphate
C10H14N5O8P (363.05799740000003)
Guanosine 2-monophosphate, also known as 2-GMP or 2-O-phosphoguanosine, belongs to the class of organic compounds known as pentose phosphates. These are carbohydrate derivatives containing a pentose substituted by one or more phosphate groups. Guanosine 2-monophosphate is a purine ribonucleoside 2-monophosphate having guanine as the nucleobase.
7-Methyl-2'-deoxyguanosine-3'-monophosphate
Adenosine 5'-phosphorothioate
C10H14N5O6PS (363.0402394000001)
Etofibrate
C18H18ClNO5 (363.08734480000004)
C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent > C98150 - Fibrate Antilipidemic Agent C - Cardiovascular system > C10 - Lipid modifying agents > C10A - Lipid modifying agents, plain > C10AB - Fibrates D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents > D000924 - Anticholesteremic Agents D009676 - Noxae > D000963 - Antimetabolites
7-(2-Chloro-6-fluorophenyl)-5-(4-chlorophenyl)-1,5,6,7-tetrahydrotetrazolo[1,5-a]pyrimidine
[(2R,5R)-5-(2-Amino-6-oxo-1H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
C10H14N5O8P (363.05799740000003)
Widely distributed in plants and animals, occurs in the hydrolysates of RNA
2-Hydroxyethyl glucosinolate
C9H17NO10S2 (363.02938620000003)
2-hydroxyethyl glucosinolate is a member of the class of compounds known as alkylglucosinolates. Alkylglucosinolates are organic compounds containing a glucosinolate moiety that carries an alkyl chain. 2-hydroxyethyl glucosinolate is soluble (in water) and an extremely strong acidic compound (based on its pKa). 2-hydroxyethyl glucosinolate can be found in capers, which makes 2-hydroxyethyl glucosinolate a potential biomarker for the consumption of this food product.
Flufenacet
C14H13F4N3O2S (363.06645660000004)
CONFIDENCE standard compound; EAWAG_UCHEM_ID 709
Guanosine monophosphate
C10H14N5O8P (363.05799740000003)
COVID info from COVID-19 Disease Map, PDB, Protein Data Bank Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS relative retention time with respect to 9-anthracene Carboxylic Acid is 0.057 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.058 5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway. 5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway.
Guanosine 5-monophosphate
C10H14N5O8P (363.05799740000003)
A purine ribonucleoside 5-monophosphate having guanine as the nucleobase.
topramezone
C16H17N3O5S (363.08888720000004)
CONFIDENCE standard compound; INTERNAL_ID 460; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3178; ORIGINAL_PRECURSOR_SCAN_NO 3177 CONFIDENCE standard compound; INTERNAL_ID 460; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3195; ORIGINAL_PRECURSOR_SCAN_NO 3193 CONFIDENCE standard compound; INTERNAL_ID 460; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3168; ORIGINAL_PRECURSOR_SCAN_NO 3166 CONFIDENCE standard compound; INTERNAL_ID 460; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3180; ORIGINAL_PRECURSOR_SCAN_NO 3179 CONFIDENCE standard compound; INTERNAL_ID 460; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3178; ORIGINAL_PRECURSOR_SCAN_NO 3176 CONFIDENCE standard compound; INTERNAL_ID 460; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3179; ORIGINAL_PRECURSOR_SCAN_NO 3177
Broperamole
C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic
Methyl 6-((4-bromophenyl)amino)-7-fluoro-1H-benzo[d]imidazole-5-carboxylate
5-NITRO-2-(4-NITROPHENYL)BENZANILIDE
C19H13N3O5 (363.08551680000005)
1-(3-Bromo-pyridine-2-yl)-3-(3-ethoxycarbonyl-phenyl)-urea
C15H14BrN3O3 (363.02184740000007)
(S)-tert-butyl 2-(5-iodo-1H-imidazol-2-yl)pyrrolidine-1-carboxylate
Thiazolidine, 3-[(4-ethoxyphenyl)sulfonyl]-2-(4-methylphenyl)- (9CI)
LOXITANE C
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist
tert-Butyl 6-bromospiro[indene-1,4-piperidine]-1-carboxylate
2-amino-6-(3-chlorophenyl)-5-methyl-3-nitro-4-phenylbenzonitrile
C20H14ClN3O2 (363.07744940000003)
L 701324
C21H14ClNO3 (363.06621640000003)
D018377 - Neurotransmitter Agents > D018683 - Excitatory Amino Acid Agents > D018691 - Excitatory Amino Acid Antagonists D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014151 - Anti-Anxiety Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants D002491 - Central Nervous System Agents > D000927 - Anticonvulsants L-701324 is a potent, orally active NMDA receptor antagonist that antagonizes the activity of the NMDA receptor by blocking its glycine B binding site. L-701324 binds with high affinity to rat brain membranes (IC50=2 nM). L-701324 has antidepressant activity[1][2][3].
1-(4-chloro-3-nitrophenyl)-2,3,4,9-tetrahydro-1H-beta-carboline hydrochloride
3-[(2S)-1-methyl-3,4-dihydro-2H-pyrrol-1-ium-2-yl]pyridine,perchloric acid,perchlorate
C10H15Cl2DN2O8 (363.034644778)
5-chloro-3-(3,5-dimethylphenyl)sulfonyl-1H-indole-2-carboxylic acid
C17H14ClNO4S (363.03320340000005)
4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]-1-benzothiophene-7-carbaldehyde
2-(2-ETHOXY-1-PROPENYL)-3-(2-HYDROXYETHYL)BENZOTHIAZOLIUM PERCHLORATE
4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzenesulfonyl chloride
C17H14ClNO4S (363.03320340000005)
tert-butyl N-[2-hydroxy-2-(4-iodophenyl)ethyl]carbamate
C13H18INO3 (363.0331388000001)
Trimethyl[2-[(trimethylsilyl)methyl]benzyl]ammonium Iodide
4-(4-bromo-2-fluorophenylamino)-6-methoxyquinazolin-7-ol
Methyl 5-[(3-chlorophenyl)amino]benzo[c][2,6]naphthyridine-8-carb oxylate
C20H14ClN3O2 (363.07744940000003)
Methyl 4-[3-(dimethylamino)propoxy]-3-iodobenzoate
C13H18INO3 (363.0331388000001)
(6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-2,10,11-triol,hydrobromide
Tocladesine
C10H11ClN5O6P (363.01354660000004)
C274 - Antineoplastic Agent > C2122 - Cell Differentiating Agent > C1934 - Differentiation Inducer C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite D000970 - Antineoplastic Agents D007155 - Immunologic Factors
1-(3-bromo-4-hydroxyphenyl)-6-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine-7,8-diol
6,7-DIHYDRO-2-PENTAFLUOROPHENYL-5H-PYRROLO(2,1-C)-1,2,4-TRIAZOLIUM TETRAFLUOROBORATE
C11H7BF9N3 (363.05892800000004)
2-Bromo-9,10-dihydro-9,9-dimethyl-10-phenylacridine
3,5-Dichloro-N-[(1,1-dimethylethoxy)carbonyl]-L-tyrosine methyl ester
C15H19Cl2NO5 (363.06402240000006)
2-bromo-7,7-dimethyl-5,7-dihydroindeno[2,1-b]carbazole
7,8-diethoxy-4-oxo-4H-benzo[4,5]thiazolo[3,2-a]pyrimidine-3-carboxylic acid ethyl ester
C16H17N3O5S (363.08888720000004)
H7
C14H19Cl2N3O2S (363.05749740000005)
Chloro(cyclooctatetraenyl)(pentamethylcyclopentadienyl)zirconium(IV)
C18H22ClZr+ (363.04570220000005)
(3-Chloro-2,6-dimethoxyphenyl)(ethoxyimino)methyl benzoate
C18H18ClNO5 (363.08734480000004)
D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents > D007096 - Imidoesters
N-(4-chloroanilino)-N-(4-chlorophenyl)-3,3-dimethyl-2-oxobutanimidamide
4-(6-iodoimidazo[1,2-a]pyridin-2-yl)-N,N-dimethylaniline
2-[(4-Phenylphenyl)sulfonylamino]pentanedioic acid
C17H17NO6S (363.07765420000004)
5-bromo-N-[4-(4-methyl-1-piperazinyl)phenyl]-2-furancarboxamide
(6R,7R)-7-[[2-amino-2-(4-hydroxyphenyl)-1-oxoethyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
C16H17N3O5S (363.08888720000004)
4-Chloro-1-naphthyl 5-methoxy-2-(2-pyridinyl)-4-pyrimidinyl ether
C20H14ClN3O2 (363.07744940000003)
2,5-dichloro-N-[5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl]benzamide
4-[(2,6-Dichlorophenyl)thio]-5-methoxy-2-(2-pyridinyl)pyrimidine
C16H11Cl2N3OS (362.99998560000006)
5-bromo-2-furancarboxylic acid [2-(3,4-dihydro-2H-quinolin-1-yl)-2-oxoethyl] ester
C16H14BrNO4 (363.01061440000007)
S-[5-(Trifluoromethyl)-4H-1,2,4-triazol-3-YL] 5-(phenylethynyl)furan-2-carbothioate
C16H8F3N3O2S (363.02893040000004)
4-{5-[(1z)-1-(2-Imino-4-Oxo-1,3-Thiazolidin-5-Ylidene)ethyl]-2-Furyl}benzenesulfonamide
4-{5-[(Z)-(2-Imino-4-Oxo-1,3-Thiazolidin-5-Ylidene)methyl]-2-Furyl}-N-Methylbenzenesulfonamide
(6,7-Dihydro-5H-cyclopenta[D]imidazo[2,1-B]thiazol-2-YL]-4,7-dihydro[1,4]thiazepine-3,6-dicarboxylic acid
Etofibrate
C18H18ClNO5 (363.08734480000004)
C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent > C98150 - Fibrate Antilipidemic Agent C - Cardiovascular system > C10 - Lipid modifying agents > C10A - Lipid modifying agents, plain > C10AB - Fibrates D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents > D000924 - Anticholesteremic Agents D009676 - Noxae > D000963 - Antimetabolites
5-Amino-11,11,14-trihydroxy-14-oxo-13,15,18-trioxa-2,4,6,9-tetraza-14lambda5-phosphatetracyclo[8.8.0.03,8.012,17]octadeca-3(8),5-dien-7-one
C10H14N5O8P (363.05799740000003)
[5-(2-amino-6-oxo-3H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen sulate
C10H13N5O8S (363.04848180000005)
N-(4,6-dimethylpyrimidin-2-yl)-N-(2-methoxycarbonylphenyl)sulfonylcarbamimidate
C15H15N4O5S- (363.07631200000003)
[(3S)-5-(2-amino-6,8-dioxo-1,7-dihydropurin-9-yl)-3-hydroxyoxolan-2-yl]methyl dihydrogen phosphate
C10H14N5O8P (363.05799740000003)
2-(6-Aminopurin-9-yl)-5-(dihydroxyphosphinothioyloxymethyl)oxolane-3,4-diol
C10H14N5O6PS (363.0402394000001)
3-Bromo-N-[2-(4-nitroanilino)ethyl]benzamide
C15H14BrN3O3 (363.02184740000007)
5-Carbamoyl-4-methyl-2-[[(3-nitrophenyl)-oxomethyl]amino]-3-thiophenecarboxylic acid methyl ester
C15H13N3O6S (363.05250380000007)
5-(4-Chlorophenyl)-2-(4-methoxyphenyl)sulfonyl-3-pyrazolamine
3-(2-chlorophenyl)-N-({2-[(3-methyl-1H-pyrazol-5-yl)carbonyl]hydrazino}carbonothioyl)acrylamide
5-bromo-N-[2-(4-methyl-1-piperazinyl)phenyl]-2-furancarboxamide
4-chloro-N-(2-methoxy-1-phenazinyl)benzamide
C20H14ClN3O2 (363.07744940000003)
Benzoic acid [2-oxo-2-[2-(phenylthio)anilino]ethyl] ester
4-[2-[2-(4-Bromo-2-chlorophenoxy)ethoxy]ethyl]morpholine
N-(4-methoxyphenyl)-N-thiophen-2-ylsulfonyl-2-furancarboxamide
5-Nitro-2-thiophenecarboxylic acid [2-oxo-2-[[oxo-[(phenylmethyl)amino]methyl]amino]ethyl] ester
C15H13N3O6S (363.05250380000007)
4-[(2-Hydroxyanilino)methylidene]-2-(2-thiazolyl)isoquinoline-1,3-dione
C19H13N3O3S (363.0677588000001)
2,5-Dimethoxybenzenesulfonic acid (1,3-dioxo-2-isoindolyl) ester
6-[[[1-(4-chlorophenyl)-5-tetrazolyl]thio]methyl]-N2,N2-dimethyl-1,3,5-triazine-2,4-diamine
3-[[4-(1,3,4-Oxadiazol-2-yl)phenyl]methyl]-2lambda6-thia-3-azatricyclo[6.3.1.04,12]dodeca-1(11),4,6,8(12),9-pentaene 2,2-dioxide
C19H13N3O3S (363.0677588000001)
2-thiophen-2-yl-N-[(E)-thiophen-3-ylmethylideneamino]quinoline-4-carboxamide
2,4-Dimethyl-6-[(2,4,5-trifluorophenyl)methyl]-5-thieno[3,4]pyrrolo[1,3-d]pyridazinone
(4R)-2-[2-[(S)-amino-(4-hydroxyphenyl)methyl]-5-hydroxy-1,3-oxazol-4-yl]-5,5-dimethyl-4H-1,3-thiazole-4-carboxylic acid
C16H17N3O5S (363.08888720000004)
2-N-[(1S)-1-(3,5-dichlorophenyl)ethyl]-2-N-methylpyrimido[4,5-d]pyrimidine-2,5,7-triamine
Cefadroxil
C16H17N3O5S (363.08888720000004)
J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01D - Other beta-lactam antibacterials > J01DB - First-generation cephalosporins A cephalosporin bearing methyl and (2R)-2-amino-2-(4-hydroxyphenyl)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton. D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D002511 - Cephalosporins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic
Fosdenopterin
C10H14N5O8P (363.05799740000003)
A - Alimentary tract and metabolism > A16 - Other alimentary tract and metabolism products > A16A - Other alimentary tract and metabolism products > A16AX - Various alimentary tract and metabolism products C78272 - Agent Affecting Nervous System
8-Oxo-2-deoxy-guanosine-5-monophosphate
C10H14N5O8P (363.05799740000003)
precursor Z hydrate
C10H14N5O8P (363.05799740000003)
A linear-fused organic heterotetracyclic compound consisting of a [1,3,2]dioxaphosphinane fused to a pyran ring which is in turn fused to a pteridine ring system. Molybdenum cofactor biosynthesis intermediate. Dehydrated derivative known as precursor Z.
Guanosine 3-monophosphate
C10H14N5O8P (363.05799740000003)
A guanosine 3-phosphate compound with a monophosphate group at the 3-position.
Guanosine 5’-phosphate
C10H14N5O8P (363.05799740000003)
Guanosine monophosphate. CAS Common Chemistry. CAS, a division of the American Chemical Society, n.d. https://commonchemistry.cas.org/detail?cas_rn=85-32-5 (retrieved 2024-06-26) (CAS RN: 85-32-5). Licensed under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0). 5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway. 5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway.
Guanosine 5'-phosphate
C10H14N5O8P (363.05799740000003)
Guanosine monophosphate. CAS Common Chemistry. CAS, a division of the American Chemical Society, n.d. https://commonchemistry.cas.org/detail?cas_rn=85-32-5 (retrieved 2024-07-01) (CAS RN: 85-32-5). Licensed under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0). 5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway. 5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway.
Tedatioxetine (hydrobromide)
C18H22BrNS (363.06562320000006)
Tedatioxetine (Lu AA24530) hydrobromide acts as a serotonin and norepinephrine (NE)-preferring triple reuptake inhibitor (TRI) and 5-HT2A, 5-HT2C, 5-HT3 and α1A-adrenergic receptor antagonist[1]. ,
[4-hydroxy-5-(6-hydroxy-2-imino-3h-purin-9-yl)-2-(hydroxymethyl)oxolan-3-yl]oxyphosphonic acid
C10H14N5O8P (363.05799740000003)
(2r,5r,6r,6as)-5-(6-aminopurin-9-yl)-2-(carboxymethyl)-6-hydroxy-5h,6h,6ah-furo[3,2-b]furan-2-carboxylic acid
C14H13N5O7 (363.08149480000003)
9-(beta-D-Xylofuranosyl)guanine delta-5'-monophosphate
C10H14N5O8P (363.05799740000003)
{"Ingredient_id": "HBIN014069","Ingredient_name": "9-(beta-D-Xylofuranosyl)guanine delta-5'-monophosphate","Alias": "47349-49-5; [(2R,3R,4R,5R)-5-(2-amino-6-oxo-3H-purin-9-yl)-3,4-dihydroxy-oxolan-2-yl]methyl dihydrogen phosphate; [(2R,3R,4R,5R)-5-(2-amino-6-oxo-3H-purin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methyl dihydrogen phosphate; 6H-Purin-6-one, 2-amino-1,9-dihydro-9-(5-O-phosphono-beta-D-xylofuranosyl)-; [(2R,3R,4R,5R)-5-(2-amino-6-oxo-3H-purin-9-yl)-3,4-dihydroxy-2-tetrahydrofuranyl]methyl dihydrogen phosphate; [(2R,3R,4R,5R)-5-(2-amino-6-keto-3H-purin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methyl dihydrogen phosphate; [(2R,3R,4R,5R)-5-(2-amino-6-oxo-3H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate","Ingredient_formula": "C10H14N5O8P","Ingredient_Smile": "C1=NC2=C(N1C3C(C(C(O3)COP(=O)(O)O)O)O)N=C(NC2=O)N","Ingredient_weight": "363.22","OB_score": "13.26019773","CAS_id": "47349-49-5","SymMap_id": "SMIT13546","TCMID_id": "NA","TCMSP_id": "MOL012818","TCM_ID_id": "NA","PubChem_id": "135612767","DrugBank_id": "NA"}
[4-hydroxy-2-(6-hydroxy-2-imino-3h-purin-9-yl)-5-(hydroxymethyl)oxolan-3-yl]oxyphosphonic acid
C10H14N5O8P (363.05799740000003)
[(2r,3r,4r,5r)-4-hydroxy-2-(6-hydroxy-2-imino-3h-purin-9-yl)-5-(hydroxymethyl)oxolan-3-yl]oxyphosphonic acid
C10H14N5O8P (363.05799740000003)
(6r,7r)-7-{[(2r)-2-amino-1-hydroxy-2-(4-hydroxyphenyl)ethylidene]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
C16H17N3O5S (363.08888720000004)
6-(4-hydroxybenzoyl)-5-(4-hydroxyphenyl)-7h-pyrrolo[2,3-d]pyrimidine-2,4-diol
C19H13N3O5 (363.08551680000005)
(2r,5s,6r,6ar)-5-(6-aminopurin-9-yl)-2-(carboxymethyl)-6-hydroxy-5h,6h,6ah-furo[3,2-b]furan-2-carboxylic acid
C14H13N5O7 (363.08149480000003)
[(2r,3s,4r,5r)-3,4-dihydroxy-5-(6-hydroxy-2-imino-3h-purin-9-yl)oxolan-2-yl]methoxyphosphonic acid
C10H14N5O8P (363.05799740000003)
5-(6-aminopurin-9-yl)-2-(carboxymethyl)-6-hydroxy-5h,6h,6ah-furo[3,2-b]furan-2-carboxylic acid
C14H13N5O7 (363.08149480000003)
[(2r,3s,4r,5s)-3,4-dihydroxy-5-(6-hydroxy-2-imino-3h-purin-9-yl)oxolan-2-yl]methoxyphosphonic acid
C10H14N5O8P (363.05799740000003)
[(z)-(3-hydroxy-1-{[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanyl}propylidene)amino]oxysulfonic acid
C9H17NO10S2 (363.02938620000003)